Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Syngene International Limited - Updates

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SYNGENE 539268

0
Movers shakers: Volumes of Tata Comm, Syngene rose the most in last 5 days

2018-07-03 moneycontrol
The market is on an uptrend this Tuesday afternoon with the Nifty up 41 points at 10,698 and the Sensex gaining 126 points at 35,390.
SYNGENE 539268 532967 532856 TATACOMM 500483 KIRIINDUS TIMETECHNO

0
Syngene International Limited - AGM/Book Closure

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SYNGENE 539268

0
Syngene International Limited - Shareholders meeting

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SYNGENE 539268

0
Syngene International Limited - Updates

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SYNGENE 539268

0
Syngene International inks pact with Zumutor Biologics

2018-05-30 thehindubusinessline
Syngene International on Wednesday informed the bourses that it has entered into a pact with US-based Zumutor Biologics for biotherapeutic antibody discovery services.
SYNGENE FORTIS 539268 532843

0
Syngene International up 1% on partnership with Zumutor Biologics

2018-05-30 moneycontrol
Share price of Syngene International rose 1.4 percent intraday Wednesday as company has entered in to partnership with Zumutor Biologics for Biotherapeutic antibody services.
SYNGENE 539268

0
Syngene International Limited - Press Release

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SYNGENE 539268

0
Biocon sells 1.88% in research arm for ₹230 cr

2018-05-18 thehindubusinessline
Biotech major Biocon has sold 1.88 per cent stake in its research arm Syngene International for around ₹230 crore. According to a filing in the exchanges, Biocon sold 37,65,574 equity shares amounting to 1.88 per cent of the equity share capital of Syngene through open market sale.
SYNGENE 539268

15
Podcast | Sensex cracks 300 points ahead of Karnataka floor test; Nifty below 10,600

2018-05-18 moneycontrol
The S&P BSE Sensex cracked 300 points on Friday amid uncertainty as to who will form the government in Karnataka and rising crude oil prices. The Nifty50 slipped below its crucial support placed at 10,600 which does not augur well for the bulls.
BAJAJ-AUTO 500800 BHUSANSTL TTAZF 532977 SRTRANSFIN TTAEY 511218 TGBL SYNDIBANK 532187 SRRQY 532480 BJJQY 500055 500034 SYNGENE INDUSINDBK TGBA ALBK 539268 532276 BAJFINANCE HINDPETRO 534809 500104 PCJEWELLER TATAGLOBAL

62
Closing Bell: Sensex down 301 pts, Nifty below 10,600; ICICI Bank, LT, Tata Motors dip 3%

2018-05-18 moneycontrol
Market Closing: Benchmark indices ended sharply lower, continuing weakness for the fourth consecutive session amid uncertainty over government formation in Karnataka, likely fiscal imbalance due to higher crude oil prices and weaker rupee.
BAJAJ-AUTO 500008 BHUSANSTL HIMATSEIDE GLBRF ARJQY 511218 532482 UCLQY SRRQY BJJQY 500570 500055 SYNGENE GRAPHITE CLGQY JETAIRWAYS 539268 ULTRACEMCO JSWSTEEL BAJAJFINSV BAJFINANCE KOTAKBANK HINDPETRO 500104 GGGBY 500228 532617 KTKBANK 532978 532538 532977 533155 SRTRANSFIN JUBLFOOD AMARAJABAT GRANULES CL 533309 JBLWY RADICO TATAMOTORS 509488 500034 514043 DALMIABHA KMBKY IBN UCLQF 532652 532497 ICICIBANK 532174 500247 TTM

0
Biocon sells 1.88% stake in Syngene for Rs230 crore

2018-05-18 livemint
New Delhi: Biocon Ltd has sold close to 2% stake in its research arm Syngene International for an estimated Rs230 crore.
SYNGENE 539268

0
Biocon sells 1.9% stake in Syngene

2018-05-18 thehindubusinessline
Biocon Ltd has sold close to 2 per cent stake in its research arm Syngene International for an estimated Rs 230 crore.
SYNGENE 539268

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...